FBP1 controls liver cancer evolution from senescent MASH hepatocytesUnderstanding metabolic dysfunction and its impact on hepatocellular carcinoma can inform potential therapeutic strategies for cancer prevention and treatment.
First US drug approved for a liver disease surging around the worldFirst FDA-approved drug for a liver disease linked to obesityResmetirom approved to treat metabolic dysfunction-associated steatohepatitis (MASH)